AstraZeneca, Russia to launch joint trial of COVID-19 vaccines before end of year

Listen

AstraZeneca said Dec. 11 that it will begin a clinical trial of its COVID-19 vaccine in combination with Russia's COVID-19 vaccine before the end of the year. 

The trial will enroll volunteers 18 years and older. 

Preliminary results have shown Russia's Sputnik V vaccine to be 90 percent effective in preventing COVID-19 infection, according to The Hill. Russia authorized the vaccine in August, the first country to do so. It began vaccinating people this week. 

Read AstraZeneca's full news release here

 

© Copyright ASC COMMUNICATIONS 2021. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

 

Featured Whitepapers

Featured Webinars